In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Roche signs new deal with PTC, this time in the area of spinal muscular atrophy

Executive Summary

Roche has received exclusive worldwide rights to genetic disorder biotech PTC Therapeutics Inc.’s program for the rare muscle weakening disease spinal muscular atrophy. The deal includes three preclinical small molecules, which could enter human testing within 18 months, plus back-up compounds.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register